On ECHEMI
Home > Drugs > Heifei Jiulian Pharma Co., Ltd.
Heifei Jiulian Pharma Co., Ltd.
  • Founded in:

    2001-08-01
  • Country:

    China China
  • Address:

    Anhui Changfeng Shuangfeng Economic Development Zone
  • Tax NO.:

    913401217300302871
  • Registered Funds:

    1 million yuan
  • Website:

  • Email:

Related Drugs
Naproxen Capsules
The main ingredient of this product is naproxen. Its chemical name is ()-alpha;-methyl-6-methoxy-2-naphthylacetic acid. Molecular formula: C14H14O3 Molecular weight: 230.26
Name Description Content CAS NO. Registered Holders
Naproxen

This product is a non-steroidal anti-inflammatory drug. Its analgesic, anti-inflammatory and antipyretic effects work by inhibiting the synthesis of prostaglandins.

More

This product is a non-steroidal anti-inflammatory drug. Its analgesic, anti-inflammatory and antipyretic effects work by inhibiting the synthesis of prostaglandins.

22204-53-1 30
Naproxen Capsules
The main ingredient of this product is naproxen. Its chemical name is ()-alpha;-methyl-6-methoxy-2-naphthylacetic acid. Molecular formula: C14H14O3 Molecular weight: 230.26
Name Description Content CAS NO. Registered Holders
Naproxen

This product is a non-steroidal anti-inflammatory drug. Its analgesic, anti-inflammatory and antipyretic effects work by inhibiting the synthesis of prostaglandins.

More

This product is a non-steroidal anti-inflammatory drug. Its analgesic, anti-inflammatory and antipyretic effects work by inhibiting the synthesis of prostaglandins.

22204-53-1 30
Prazosin Hydrochloride Tablets
The main ingredient and chemical name of this product are: 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl)piperazine hydrochloride
Name Description Content CAS NO. Registered Holders
Prazosin hydrochloride

1. A selective postsynaptic α1 receptor blocker that relaxes vascular smooth muscle, dilates peripheral blood vessels, reduces peripheral vascular resistance, and lowers blood pressure; 2. It dilates arteries and veins, reduces cardiac preload and afterload, improves cardiac function, and has a rapid onset of action in the treatment of heart failure, reaching a peak in 1 hour and lasting for 6 hours; 3. It has little effect on renal blood flow and glomerular filtration rate, and can relieve dysuria in patients with prostatic hyperplasia by blocking α1 receptors in the bladder neck, prostate capsule and gland, and urethra; 4. Animal experiments have shown that most drugs are bound to α1 acid glycoprotein, and only 5% of the drugs exist in free form.

More

1. A selective postsynaptic α1 receptor blocker that relaxes vascular smooth muscle, dilates peripheral blood vessels, reduces peripheral vascular resistance, and lowers blood pressure; 2. It dilates arteries and veins, reduces cardiac preload and afterload, improves cardiac function, and has a rapid onset of action in the treatment of heart failure, reaching a peak in 1 hour and lasting for 6 hours; 3. It has little effect on renal blood flow and glomerular filtration rate, and can relieve dysuria in patients with prostatic hyperplasia by blocking α1 receptors in the bladder neck, prostate capsule and gland, and urethra; 4. Animal experiments have shown that most drugs are bound to α1 acid glycoprotein, and only 5% of the drugs exist in free form.

19237-84-4 20
Allopurinol Tablets
The main ingredient of this product is allopurinol, whose chemical name is 1H-pyrazolo[3,4-d]pyrimidine-4-ol.
Name Description Content CAS NO. Registered Holders
Allopurinol

Inhibit uric acid synthesis by inhibiting xanthine oxidase to prevent hypoxanthine and xanthine from being metabolized into uric acid, thereby reducing uric acid production, lowering the uric acid content in the blood and urine, preventing the deposition of uric acid crystals and helping to redissolve uric acid crystals in the tissues of gout patients; it can also inhibit new purine synthesis in the body by inhibiting the action of hypoxanthine-guanine phosphate nuclease.

More

Inhibit uric acid synthesis by inhibiting xanthine oxidase to prevent hypoxanthine and xanthine from being metabolized into uric acid, thereby reducing uric acid production, lowering the uric acid content in the blood and urine, preventing the deposition of uric acid crystals and helping to redissolve uric acid crystals in the tissues of gout patients; it can also inhibit new purine synthesis in the body by inhibiting the action of hypoxanthine-guanine phosphate nuclease.

315-30-0 64
Sodium Alginate Diester Tablets
The main ingredients of this product are: sodium alginate diester.
Name Description Content CAS NO. Registered Holders
Alginic Sodium Diester

This product is an acidic polysaccharide drug with strong dispersing and emulsifying properties, improving the viscoelasticity of blood rheology, and an anticoagulant effect equivalent to 1/3 to 1/2 of heparin. It prevents platelet adhesion to collagen and inhibits platelet aggregation. It has prostaglandin (PGI2)-like effects such as anti-thrombosis, lowering blood viscosity, micro-arteriovenous spasm, and red blood cell and platelet depolymerization. It can significantly lower blood lipids, cholesterol, triglycerides, low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL), increase high-density lipoprotein (HDL), inhibit the occurrence and development of atherosclerotic lesions, dilate peripheral blood vessels, improve microcirculation, and inhibit the formation of thrombi in arteries and veins. It also has multiple functions such as lowering blood sugar and blood pressure.

More

This product is an acidic polysaccharide drug with strong dispersing and emulsifying properties, improving the viscoelasticity of blood rheology, and an anticoagulant effect equivalent to 1/3 to 1/2 of heparin. It prevents platelet adhesion to collagen and inhibits platelet aggregation. It has prostaglandin (PGI2)-like effects such as anti-thrombosis, lowering blood viscosity, micro-arteriovenous spasm, and red blood cell and platelet depolymerization. It can significantly lower blood lipids, cholesterol, triglycerides, low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL), increase high-density lipoprotein (HDL), inhibit the occurrence and development of atherosclerotic lesions, dilate peripheral blood vessels, improve microcirculation, and inhibit the formation of thrombi in arteries and veins. It also has multiple functions such as lowering blood sugar and blood pressure.

9005-40-7 11
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.